UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 374

Sortiert nach

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

The Lancet (British edition), 2019-01, Vol.393 (10166), p.31-39

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological Treatment and Current Management of Peripheral Artery Disease

Circulation research, 2015-04, Vol.116 (9), p.1579-1598

2015

Link zum Volltext

Verfügbarkeit prüfen

Rivaroxaban in Peripheral Artery Disease after Revascularization

The New England journal of medicine, 2020-05, Vol.382 (21), p.1994-2004

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Circulation (New York, N.Y.), 2019-05, Vol.139 (22), p.2528-2536

2019

Link zum Volltext

Verfügbarkeit prüfen

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

The American heart journal, 2018-06, Vol.200, p.83-89

2018

Link zum Volltext

Verfügbarkeit prüfen

Microvascular Disease, Peripheral Artery Disease, and Amputation

Circulation (New York, N.Y.), 2019-08, Vol.140 (6), p.449-458

2019

Link zum Volltext

Verfügbarkeit prüfen

DECLARE‐TIMI 58: Participants’ baseline characteristics

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1102-1110

2018

Link zum Volltext

Verfügbarkeit prüfen

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial

Journal of the American College of Cardiology, 2016-03, Vol.67 (10), p.1145-1154

2016

Link zum Volltext

Verfügbarkeit prüfen

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

The Lancet (British edition), 2012-10, Vol.380 (9850), p.1317-1324

2012

Link zum Volltext

Verfügbarkeit prüfen

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

The American heart journal, 2014-04, Vol.167 (4), p.437-444.e5

2014

Link zum Volltext

Verfügbarkeit prüfen

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

Clinical chemistry (Baltimore, Md.), 2012-01, Vol.58 (1), p.257-266

2012

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial

The American heart journal, 2022-04, Vol.246, p.136-143

2022

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Journal of the American College of Cardiology, 2014-04, Vol.63 (16), p.1644-1653

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of transitioning to virtual delivery of a cardiovascular health improvement program for Latinos during the COVID-19 pandemic

BMC public health, 2022-10, Vol.22 (1), p.1-1935, Article 1935

2022

Link zum Volltext

Verfügbarkeit prüfen

At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers

BMC infectious diseases, 2022-05, Vol.22 (1), p.443-443, Article 443

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

The American heart journal, 2009-09, Vol.158 (3), p.335-341.e3

2009

Link zum Volltext

Verfügbarkeit prüfen

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Journal of the American Heart Association, 2021-02, Vol.10 (4), p.e017008-e017008

2021

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

The lancet oncology, 2018-12, Vol.19 (12), p.1579-1589

2018

Link zum Volltext

Verfügbarkeit prüfen

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial

Journal of the American Heart Association, 2020-05, Vol.9 (10), p.e015331

2020

Link zum Volltext

Verfügbarkeit prüfen

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Circulation (New York, N.Y.), 2018-01, Vol.137 (4), p.338-350

2018

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50

Journal of the American Heart Association, 2021-05, Vol.10 (9), p.e018673-e018673

2021

Link zum Volltext

Verfügbarkeit prüfen

Studying the coagulopathy of COVID-19

The Lancet (British edition), 2022-01, Vol.399 (10320), p.118-119

2022

Link zum Volltext

Verfügbarkeit prüfen

Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease

Journal of Cardiovascular Pharmacology and Therapeutics, 2022-01, Vol.27, p.10742484211056115-10742484211056115

2022

Link zum Volltext

Verfügbarkeit prüfen

Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD

Journal of the American Heart Association, 2022-06, Vol.11 (12), p.e024655-e024655

2022

Link zum Volltext

Verfügbarkeit prüfen

Contemporary Medical Management of Peripheral Artery Disease

Circulation research, 2021-06, Vol.128 (12), p.1868-1884

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 374

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(348)
Mit Volltextzugriff
(347)

Publikationsform

Artikel
(370)
Buchkapitel
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(213)
Science & Technology
(213)
Humans
(174)
Cardiovascular System & Cardiology
(173)
Cardiac & Cardiovascular Systems
(153)
Male
(97)
Female
(93)
Aged
(89)
Middle Aged
(80)
Treatment Outcome
(66)
Risk Factors
(65)
Peripheral Vascular Disease
(61)
Myocardial Infarction
(49)
Cardiovascular Disease
(46)
Cardiology
(45)
Heart Attacks
(44)
Peripheral Artery Disease
(44)
Stroke
(40)
Secondary Prevention
(34)
Ischemia
(33)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Pharmacological Treatment and Current Management of Peripheral Artery Disease

Rivaroxaban in Peripheral Artery Disease after Revascularization

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Microvascular Disease, Peripheral Artery Disease, and Amputation

DECLARE‐TIMI 58: Participants’ baseline characteristics

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial

Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Impact of transitioning to virtual delivery of a cardiovascular health improvement program for Latinos during the COVID-19 pandemic

At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50

Studying the coagulopathy of COVID-19

Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease

Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD

Contemporary Medical Management of Peripheral Artery Disease

Suchergebnisse filtern